摘要
免疫性血小板减少症发病机制较为复杂,研究表明,DNA甲基化异常可能参与免疫性血小板减少症的发病过程。地西他滨为一种特异的DNA甲基转移酶抑制剂,低剂量时主要表现为去甲基化作用,目前作为一种新药被用于难治性免疫性血小板减少症的治疗。本文就DNA甲基化在免疫性血小板减少症中的作用机制及地西他滨在免疫性血小板减少症中的应用和研究进展进行综述。
The pathogenesis of immune thrombocytopenia is complicated. Studies have shown that abnormal DNA methylation may be involved in the pathogenesis of immune thrombocytopenia. Decitabine is a specific DNA methyltransferase inhibitor, which is mainly manifested as demethylation at low doses. It is currently used as a new drug for the treatment of refractory immune thrombocytopenia. Therefore, this paper reviews the mechanism of DNA methylation in immune thrombocytopenia and the application and research progress of decitabine in immune thrombocytopenia.
作者
邹雅倩
蔡惠丽
江菲
郭静明
ZOU Yaqian;CAI Huili;JIANG Fei;GUO Jingming(Department of Hematology,the First Clinical Medical College of Three Gorges University,Yichang Central People's Hospital,Yichang 443003,China)
出处
《生命的化学》
CAS
2021年第9期1950-1954,共5页
Chemistry of Life
基金
湖北省自然科学基金青年项目(2017CFB334)
湖北省教育厅科学研究项目(B2017018)
湖北省卫生和计划生育委员会科研项目(WJ2017M222)。
